{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T17:17:45Z","timestamp":1783099065850,"version":"3.54.6"},"reference-count":57,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011773","name":"Conseil r\u00e9gional de Bourgogne-Franche-Comt\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011773","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.xcrm.2026.102632","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T16:02:37Z","timestamp":1772208157000},"page":"102632","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Valrubicin-loaded immunoliposomes targeting antigens on immunosuppressive cells to circumvent resistance to cancer immunotherapy"],"prefix":"10.1016","volume":"7","author":[{"given":"Aleksandra","family":"Georgievski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00e9mie","family":"Blanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Bruchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassandre","family":"Pignol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Simon","family":"Bellaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Garrido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1615-6769","authenticated-orcid":false,"given":"Ronan","family":"Qu\u00e9r\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2026.102632_bib1","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41568-020-0285-7","article-title":"The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy","volume":"20","author":"Bruni","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xcrm.2026.102632_bib2","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2026.102632_bib3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12943-020-1144-6","article-title":"Predictive biomarkers and mechanisms underlying resistance to PD1\/PD-L1 blockade cancer immunotherapy","volume":"19","author":"Ren","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.xcrm.2026.102632_bib4","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune checkpoint therapy-current perspectives and future directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2026.102632_bib5","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1038\/s41590-019-0512-0","article-title":"Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups","volume":"20","author":"Andrews","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.xcrm.2026.102632_bib6","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.1016\/j.cell.2024.07.016","article-title":"LAG-3 and PD-1 synergize on CD8(+) T cells to drive T cell exhaustion and hinder autocrine IFN-gamma-dependent anti-tumor immunity","volume":"187","author":"Andrews","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2026.102632_bib7","doi-asserted-by":"crossref","first-page":"5030","DOI":"10.1158\/1078-0432.CCR-21-2390","article-title":"Molecular Pathways and Mechanisms of LAG3 in Cancer Therapy","volume":"28","author":"Andrews","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102632_bib8","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/s41590-023-01569-z","article-title":"LAG-3 as the third checkpoint inhibitor","volume":"24","author":"Aggarwal","year":"2023","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.xcrm.2026.102632_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003776","article-title":"Phase I\/II study of the LAG-3 inhibitor ieramilimab (LAG525) \u00b1 anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies","volume":"10","author":"Sch\u00f6ffski","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2026.102632_bib10","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1200\/JCO.23.02172","article-title":"Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma","volume":"42","author":"Hamid","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102632_bib11","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13045-023-01499-1","article-title":"Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy","volume":"16","author":"Cai","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.xcrm.2026.102632_bib12","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41586-022-05368-8","article-title":"Neoadjuvant relatlimab and nivolumab in resectable melanoma","volume":"611","author":"Amaria","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.102632_bib13","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1158\/1078-0432.CCR-22-0701","article-title":"Facts and Hopes in Immunotherapy for Early-Stage Triple-Negative Breast Cancer","volume":"29","author":"Nederlof","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102632_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000110","article-title":"Identification of tumor immune infiltration-associated lncRNAs for improving prognosis and immunotherapy response of patients with non-small cell lung cancer","volume":"8","author":"Sun","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2026.102632_bib15","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12943-023-01740-y","article-title":"Lung cancer immunotherapy: progress, pitfalls, and promises","volume":"22","author":"Lahiri","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.xcrm.2026.102632_bib16","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nature20554","article-title":"Overcoming resistance to checkpoint blockade therapy by targeting PI3Kgamma in myeloid cells","volume":"539","author":"De Henau","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.102632_bib17","doi-asserted-by":"crossref","first-page":"11774","DOI":"10.1073\/pnas.1410626111","article-title":"Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells","volume":"111","author":"Kim","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2026.102632_bib18","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ccell.2021.12.009","article-title":"MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells","volume":"40","author":"Limagne","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2026.102632_bib19","doi-asserted-by":"crossref","first-page":"5146","DOI":"10.1038\/s41467-023-40844-3","article-title":"Immunotherapy targeting different immune compartments in combination with radiation therapy induces regression of resistant tumors","volume":"14","author":"Rudqvist","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.102632_bib20","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.150735","article-title":"VEGFR2 activity on myeloid cells mediates immune suppression in the tumor microenvironment","volume":"6","author":"Zhang","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.xcrm.2026.102632_bib21","article-title":"Targeting VEGF\/VEGFR to Modulate Antitumor Immunity","volume":"9","author":"Yang","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2026.102632_bib22","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","article-title":"Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential","volume":"161","author":"Sharma","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2026.102632_bib23","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13045-022-01282-8","article-title":"Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets","volume":"15","author":"Tie","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.xcrm.2026.102632_bib24","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.it.2016.01.004","article-title":"The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment","volume":"37","author":"Kumar","year":"2016","journal-title":"Trends Immunol."},{"key":"10.1016\/j.xcrm.2026.102632_bib25","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41392-021-00670-9","article-title":"Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer","volume":"6","author":"Li","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.xcrm.2026.102632_bib26","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41590-021-00967-5","article-title":"Orchestration of myeloid-derived suppressor cells in the tumor microenvironment by ubiquitous cellular protein TCTP released by tumor cells","volume":"22","author":"Hangai","year":"2021","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.xcrm.2026.102632_bib27","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumour-associated macrophages as treatment targets in oncology","volume":"14","author":"Mantovani","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102632_bib28","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41571-022-00620-6","article-title":"Clinical relevance of tumour-associated macrophages","volume":"19","author":"Pittet","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102632_bib29","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41586-023-06256-5","article-title":"Reprogramming tumour-associated macrophages to outcompete cancer cells","volume":"619","author":"Zhang","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.102632_bib30","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41571-019-0222-4","article-title":"Tumour-associated neutrophils in patients with cancer","volume":"16","author":"Shaul","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102632_bib31","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ccell.2016.06.001","article-title":"Origin and Role of a Subset of Tumor-Associated Neutrophils with Antigen-Presenting Cell Features in Early-Stage Human Lung Cancer","volume":"30","author":"Singhal","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2026.102632_bib32","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.cell.2015.05.025","article-title":"ER Stress Sensor XBP1 Controls Anti-tumor Immunity by Disrupting Dendritic Cell Homeostasis","volume":"161","author":"Cubillos-Ruiz","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2026.102632_bib33","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200264","article-title":"Tumor-infiltrating dendritic cell states are conserved across solid human cancers","volume":"218","author":"Gerhard","year":"2021","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.xcrm.2026.102632_bib34","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1016\/j.cell.2023.07.034","article-title":"A pan-cancer single-cell panorama of human natural killer cells","volume":"186","author":"Tang","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2026.102632_bib35","article-title":"Antibody-based cancer immunotherapy by targeting regulatory T cells","volume":"13","author":"Li","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.xcrm.2026.102632_bib36","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s12026-021-09211-6","article-title":"Recent advances in the role of Th17\/Treg cells in tumor immunity and tumor therapy","volume":"69","author":"Qianmei","year":"2021","journal-title":"Immunol. Res."},{"key":"10.1016\/j.xcrm.2026.102632_bib37","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/s41591-022-02178-3","article-title":"Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma","volume":"29","author":"Larrayoz","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.102632_bib38","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1158\/0008-5472.CAN-17-0491","article-title":"Small-Molecule Inhibition of PD-1 Transcription Is an Effective Alternative to Antibody Blockade in Cancer Therapy","volume":"78","author":"Taylor","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102632_bib39","article-title":"Engineering immunoproteasome-expressing mesenchymal stromal cells: A potent cellular vaccine for lymphoma and melanoma in mice","volume":"2","author":"Abusarah","year":"2021","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.xcrm.2026.102632_bib40","doi-asserted-by":"crossref","first-page":"E966","DOI":"10.1073\/pnas.1500712112","article-title":"Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK","volume":"112","author":"Sagiv-Barfi","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2026.102632_bib41","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.3389\/fonc.2020.01195","article-title":"Multi-Omics Characterization of the 4T1 Murine Mammary Gland Tumor Model","volume":"10","author":"Schr\u00f6rs","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.xcrm.2026.102632_bib42","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15082366","article-title":"Regression and Eradication of Triple-Negative Breast Carcinoma in 4T1 Mouse Model by Combination Immunotherapies","volume":"15","author":"Nahar","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.xcrm.2026.102632_bib43","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1038\/s41467-019-09415-3","article-title":"Crizotinib-induced immunogenic cell death in non-small cell lung cancer","volume":"10","author":"Liu","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.102632_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22126309","article-title":"Effects of a Unique Combination of the Whole-Body Low Dose Radiotherapy with Inactivation of Two Immune Checkpoints and\/or a Heat Shock Protein on the Transplantable Lung Cancer in Mice","volume":"22","author":"Nowosielska","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.xcrm.2026.102632_bib45","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41423-023-01112-y","article-title":"The BCL-2 inhibitor APG-2575 resets tumor-associated macrophages toward the M1 phenotype, promoting a favorable response to anti-PD-1 therapy via NLRP3 activation","volume":"21","author":"Luo","year":"2024","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.xcrm.2026.102632_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2023.122463","article-title":"Nano-enhanced immunotherapy: Targeting the immunosuppressive tumor microenvironment","volume":"305","author":"Jin","year":"2024","journal-title":"Biomaterials"},{"key":"10.1016\/j.xcrm.2026.102632_bib47","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s41568-019-0186-9","article-title":"Improving cancer immunotherapy through nanotechnology","volume":"19","author":"Goldberg","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xcrm.2026.102632_bib48","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.ade0625","article-title":"Engineering an active immunotherapy for personalized cancer treatment and prevention of recurrence","volume":"9","author":"Wu","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.xcrm.2026.102632_bib49","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/s41419-024-06715-5","article-title":"Valrubicin-loaded immunoliposomes for specific vesicle-mediated cell death in the treatment of hematological cancers","volume":"15","author":"Georgievski","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.xcrm.2026.102632_bib50","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41586-020-2134-y","article-title":"A conserved dendritic-cell regulatory program limits antitumour immunity","volume":"580","author":"Maier","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.102632_bib51","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s12307-013-0133-3","article-title":"Immunosuppressive mechanisms of regulatory dendritic cells in cancer","volume":"6","author":"Shurin","year":"2013","journal-title":"Cancer Microenviron."},{"key":"10.1016\/j.xcrm.2026.102632_bib52","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1158\/2159-8290.CD-24-1232","article-title":"Tumor-associated NK Cells Regulate Distinct CD8+ T-cell Differentiation Program in Cancer and Contribute to Resistance against Immune Checkpoint Blockers","volume":"15","author":"Song","year":"2025","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2026.102632_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101405","article-title":"Anti-CTLA-4 and anti-PD-1 immunotherapies repress tumor progression in preclinical breast and colon model with independent regulatory T cells response","volume":"20","author":"Rupp","year":"2022","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.xcrm.2026.102632_bib54","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1158\/2326-6066.CIR-16-0365","article-title":"The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1\/PD-L1 Antibody Blockade","volume":"5","author":"Li","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.xcrm.2026.102632_bib55","doi-asserted-by":"crossref","first-page":"747","DOI":"10.7150\/thno.65828","article-title":"Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression in tumor cells","volume":"12","author":"Tu","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.xcrm.2026.102632_bib56","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1080\/17425247.2018.1517747","article-title":"Clinical translation of immunoliposomes for cancer therapy: recent perspectives","volume":"15","author":"Wang","year":"2018","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.xcrm.2026.102632_bib57","doi-asserted-by":"crossref","DOI":"10.3390\/life14060672","article-title":"Targeted Liposomal Drug Delivery: Overview of the Current Applications and Challenges","volume":"14","author":"Gatto","year":"2024","journal-title":"Life"}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126000492?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126000492?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T16:25:12Z","timestamp":1783095912000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379126000492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2666379126000492"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102632","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Valrubicin-loaded immunoliposomes targeting antigens on immunosuppressive cells to circumvent resistance to cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102632","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102632"}}